Please assess the completion status of the following clinical trial:

Trial Title: Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. PD patients (aged ≥18 years) are dialyzed with lactate-buffered glucose dialysate, using a twinbag connection system (Baxter Healthcare, Guangzhou, China).~2. For entry , all patients are required to meet all diagnositic criteria of the International RLS Study Group (IRLSSG), to have a baseline total score \>15 on the Study Group's International RLS Rating Scale (IRLS), and to have experienced RLS symptoms at least 2-3 days per week throughout the perior 3 months.~3. Each patient should write informed consent.~4. All patients are required to be interviewed to the frequency required by the research process.~Exclusion Criteria:~1. Patients with severe gastrointestinal illness can not tolerate oral drugs.~2. Patients who work on a shift schedule are not allowed to participate.~3. Women with childbearing potential are excluded for pregnancy, inadequate contraception, or current breastfeeding of a child.~4. Patients are also excluded for current use (within 14 days before baseline) of medications that might affect RLS symptoms, e.g., levodopa, dopamine agonists or antagonists, hypnotics, lithium formulations, or antidepressants.~5. Patients with serum ferritin ≤200 ng/ml, or Hb \<110g/L, or Kt/V \<1.7 are excluded.~6. Patients with severe and unstable inflammation disease (active systemic infection, acute cardiovascular disease, active liver disease, active connective tissue disorder, ,and cancer within 1 year of radiotherapy and chemotherapy, )

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
- Control group (Type: PLACEBO_COMPARATOR): Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).